{"id":71500,"date":"2026-05-20T10:25:00","date_gmt":"2026-05-20T10:25:00","guid":{"rendered":"https:\/\/medsbase.com\/thymosin-alpha-1\/"},"modified":"2026-05-21T07:14:09","modified_gmt":"2026-05-21T07:14:09","slug":"thymosin-alpha-1","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/thymosin-alpha-1\/","title":{"rendered":"Thymosin Alpha-1 (T\u03b11 \/ Thymalfasin)"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is Thymosin Alpha-1?<\/h3>\n

Thymosin Alpha-1<\/strong> (T\u03b11; clinically Thymalfasin \/ Zadaxin<\/strong>) is a synthetic 28-amino-acid peptide (CAS 62304-98-7 free, 62304-94-3 acetate; MW 3,108.3 g\/mol) corresponding to the N-terminal 28 residues of the natural thymus-derived prothymosin precursor. Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH. Mechanism: activates TLR9 and TLR2<\/strong> on dendritic cells and macrophages, drives Th1-polarised T-cell maturation, increases CD4+ and CD8+ T-cell proliferation, and enhances IFN-\u03b3 \/ IL-2 cytokine production. Clinically approved in 35+ countries (under brand Zadaxin) for chronic hepatitis B and C, and used as immune-support adjuvant in oncology research. For laboratory research use only. Defined single-sequence 28-aa peptide<\/em> \u2014 distinct from the multi-component Thymalin<\/a> polypeptide preparation.<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Lyophilized \u226599% HPLC-verified Thymosin Alpha-1 acetate \u00b7 COA available on request \u00b7 Discreet temperature-stable packaging \u00b7 Worldwide research-supply courier \u00b7 1,400+ verified klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
Compound Class<\/strong><\/td>\nSynthetic 28-aa immunomodulatory peptide (prothymosin \u03b1 N-terminal fragment); TLR9\/TLR2 agonist; defined single-sequence thymic peptide<\/td>\n<\/tr>\n
Chemical Name<\/strong><\/td>\nThymosin Alpha-1 (synonyms: T\u03b11, Thymalfasin, Zadaxin)<\/td>\n<\/tr>\n
CAS-nummer<\/strong><\/td>\n62304-98-7 (free peptide); 62304-94-3 (acetate salt)<\/td>\n<\/tr>\n
Sequentie<\/strong><\/td>\nAc-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH (28 amino acids; N-terminal acetylation; corresponds to residues 2\u201329 of prothymosin \u03b1)<\/td>\n<\/tr>\n
Moleculair gewicht<\/strong><\/td>\n3,108.3 g\/mol<\/td>\n<\/tr>\n
Molecuulformule<\/strong><\/td>\nC129<\/sub>H215<\/sub>N33<\/sub>O55<\/sub>; MW 3108.32 g\/mol (28-aa N-terminal acetylated peptide, free acid C-terminus).<\/td>\n<\/tr>\n
Werkingsmechanisme<\/strong><\/td>\nActivates TLR9<\/strong> (toll-like receptor 9) on dendritic cells and plasmacytoid DCs, with secondary TLR2<\/strong> engagement. Downstream effects: MyD88-IRAK-NF-\u03baB signalling cascade; Th1-polarised T-cell maturation; increased CD4+ \/ CD8+ T-cell proliferation; enhanced IFN-\u03b3 and IL-2 production; activated NK cell cytotoxicity; modulation of regulatory T-cell (Treg) balance. Net effect is broad immune-restoration \/ Th1-enhancement.<\/td>\n<\/tr>\n
Form \/ Purity \/ Storage<\/strong><\/td>\nLyophilized white-to-off-white powder, \u226599% HPLC. Store 2\u20138 \u00b0C short-term, \u221220 \u00b0C long-term. Reconstituted: 2\u20138 \u00b0C, use within 30 days. Avoid freeze-thaw.<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nFor laboratory research use only. Zadaxin (clinical T\u03b11) is approved in 35+ countries for chronic HBV and HCV (not FDA-approved in the US). Not on the WADA Prohibited List.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Mechanism of Action \u2014 TLR9 \/ TLR2 Activation + Th1 Polarisation<\/h2>\n

Thymosin Alpha-1 is a defined-sequence immune-modulating peptide with extensive characterised mechanism in published research:<\/p>\n